1.075
0.47%
0.005
After Hours:
1.07
-0.005
-0.47%
Achilles Therapeutics Plc Adr Stock (ACHL) Forecast
The Achilles Therapeutics Plc Adr (ACHL) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $6.6114, representing a +515.02% increase from the current price of $1.075. The highest analyst price target is $6.4224, and the lowest is $6.8005.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month ACHL Price Target
Average 6.2325
(+479.77% Upside)
Is Achilles Therapeutics Plc Adr (ACHL) A Buy Now?
Oscillators
Name | Value | Action |
---|---|---|
RSI(14) | 63.88 | Neutral |
STOCH(9,6) | 68.55 | Neutral |
STOCHRSI(14) | 81.74 | Sell |
MACD(12,26) | 0.0221 | Sell |
ADX(14) | 19.79 | Neutral |
William %R | -34.64 | Neutral |
CCI(14) | 70.05 | Neutral |
Buy: 0
Sell: 2
Neutral: 5
Summary: Neutral
Moving Averages
Period | Simple | Exponential |
---|---|---|
MA10 |
1.0637
Buy
|
1.0631
Buy
|
MA20 |
1.0498
Buy
|
1.0481
Buy
|
MA50 |
1.0174
Buy
|
0.9969
Buy
|
MA100 |
0.8946
Buy
|
0.9487
Buy
|
MA200 |
0.9407
Buy
|
0.9239
Buy
|
Buy: 10
Sell: 0
Neutral: 0
Summary: Buy
According to our latest analysis, ACHL could be considered a Strong Buy, with 17 technical analysis indicators signaling 10 Buy signals, 2 signaling Sell signals and 5 Neutral signals. This might be a good time to open fresh positions on ACHL, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 63.88 indicates that ACHL is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 68.55 indicates that ACHL is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 81.74 indicates that ACHL is oversold. This suggests that ACHL price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 19.79 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 70.05 indicates that ACHL is still overbought but not to an extreme extent.
Long-term ACHL price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Achilles Therapeutics Plc Adr financial reports and earnings history, Achilles Therapeutics Plc Adr (ACHL) stock could reach $10.58 by 2030, $35.86 by 2040 and $72.68 by 2050. See the projected annual prices until 2050 of the Achilles Therapeutics Plc Adr stock below:
- Achilles Therapeutics Plc Adr (ACHL) is expected to reach an average price of $46.04 in 2035, with a high prediction of $45.43 and a low estimate of $43.10. This indicates an $4,182% rise from the last recorded price of $1.075.
- Achilles Therapeutics Plc Adr (ACHL) stock is projected to chart a bullish course in 2040, with an average price target of $35.08, representing an $3,163% surge from its current level. The forecast ranges from a conservative $35.31 to a sky-high $35.86.
- Our analysts predict Achilles Therapeutics Plc Adr (ACHL) to jump 641.73% by 2045, soaring from $8.0236 to an average price of $7.9736, potentially reaching $9.5885. While $8.0236 is the low estimate, the potential upside is significant.
- Achilles Therapeutics Plc Adr (ACHL) stock is expected to climb by 2050, reaching an average of $70.96, a $6,501% jump from its current level. However, a wide range of estimates exists, with high and low targets of $72.68 and $71.05, respectively, highlighting the market's uncertainty.
Achilles Therapeutics Plc Adr Stock (ACHL) Year by Year Forecast
Achilles Therapeutics Plc Adr Stock (ACHL) Price Forecast for 2025
Achilles Therapeutics Plc Adr Stock (ACHL) is expected to reach an average price of $6.2325 in 2025, with a high prediction of $7.303 and a low estimate of $5.162. This indicates an +479.77% rise from the last recorded price of $1.075.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2025 | $6.4443 | $6.8005 | $6.4224 | +499.47% |
February, 2025 | $6.8481 | $6.1821 | $6.2902 | +537.03% |
March, 2025 | $7.0119 | $7.00 | $6.9119 | +552.27% |
April, 2025 | $7.1316 | $7.1916 | $6.9716 | +563.41% |
May, 2025 | $6.9954 | $7.2554 | $7.2235 | +550.74% |
June, 2025 | $7.4792 | $7.1473 | $7.0073 | +595.74% |
July, 2025 | $6.959 | $7.389 | $7.303 | +547.35% |
August, 2025 | $6.6828 | $6.7728 | $6.8449 | +521.65% |
September, 2025 | $6.3966 | $6.4766 | $6.4787 | +495.03% |
October, 2025 | $5.5363 | $6.0863 | $5.9944 | +415.01% |
November, 2025 | $5.3101 | $5.2982 | $5.2723 | +393.97% |
December, 2025 | $5.5899 | $5.162 | $5.0861 | +419.99% |
Achilles Therapeutics Plc Adr Stock (ACHL) Price Forecast for 2026
The predicted value for Achilles Therapeutics Plc Adr (ACHL) in 2026 is set at an average of $4.4692. Estimates vary from a peak of $5.8391 to a trough of $3.0993, indicating an +315.74% surge from the present price of $1.075.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2026 | $5.5237 | $5.5658 | $5.4118 | +413.83% |
February, 2026 | $5.4075 | $5.6075 | $5.4396 | +403.02% |
March, 2026 | $5.6613 | $5.2094 | $5.1734 | +426.63% |
April, 2026 | $5.411 | $5.501 | $5.8391 | +403.35% |
May, 2026 | $5.0948 | $5.1148 | $5.307 | +373.94% |
June, 2026 | $4.8986 | $4.9036 | $4.9567 | +355.69% |
July, 2026 | $4.6709 | $4.7684 | $4.7746 | +334.50% |
August, 2026 | $4.5022 | $4.562 | $4.5794 | +318.81% |
September, 2026 | $3.9619 | $4.0011 | $4.3581 | +268.55% |
October, 2026 | $3.7057 | $3.7057 | $3.8479 | +244.72% |
November, 2026 | $3.2595 | $3.3895 | $3.5717 | +203.21% |
December, 2026 | $3.058 | $3.0993 | $3.1855 | +184.47% |
Achilles Therapeutics Plc Adr Stock (ACHL) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Achilles Therapeutics Plc Adr (ACHL) is $7.2425, with a high forecast of $14.42 and a low forecast of $0.0652. This indicates an +573.72% increase from the last price of $1.075.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2027 | $2.8381 | $2.8671 | $2.9652 | +164.01% |
February, 2027 | $2.5593 | $2.5727 | $2.7192 | +138.07% |
March, 2027 | $2.1733 | $2.2046 | $2.4288 | +102.17% |
April, 2027 | $1.9144 | $1.9303 | $2.0487 | +78.08% |
May, 2027 | $1.6239 | $1.6356 | $1.8164 | +51.06% |
June, 2027 | $1.114 | $1.254 | $1.4802 | +3.62% |
July, 2027 | $0.7178 | $0.8677 | $1.0374 | -33.23% |
August, 2027 | $0.2516 | $0.2456 | $0.2737 | -76.60% |
September, 2027 | $0.2613 | $0.0994 | $0.2473 | -75.69% |
October, 2027 | $0.1213 | $0.0652 | $0.1774 | -88.72% |
November, 2027 | $13.82 | $12.85 | $13.29 | +1,186% |
December, 2027 | $14.64 | $14.65 | $14.42 | +1,262% |
Achilles Therapeutics Plc Adr Stock (ACHL) Price Forecast for 2028
In 2028, Achilles Therapeutics Plc Adr (ACHL) is projected to reach an average price of $17.64, with a high projection of $19.59 and a low estimate of $15.68. This indicates an +1,540% rise from the last price of $1.075.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2028 | $16.96 | $15.68 | $16.26 | +1,478% |
February, 2028 | $20.24 | $19.40 | $19.59 | +1,782% |
March, 2028 | $18.55 | $18.97 | $19.54 | +1,625% |
April, 2028 | $17.78 | $18.77 | $18.72 | +1,554% |
May, 2028 | $17.26 | $16.63 | $16.38 | +1,506% |
June, 2028 | $18.44 | $17.56 | $17.20 | +1,615% |
July, 2028 | $17.85 | $18.30 | $17.97 | +1,560% |
August, 2028 | $18.00 | $17.36 | $17.62 | +1,574% |
September, 2028 | $17.89 | $17.96 | $17.76 | +1,564% |
October, 2028 | $17.57 | $17.63 | $17.52 | +1,535% |
November, 2028 | $17.20 | $17.29 | $17.52 | +1,500% |
December, 2028 | $17.09 | $17.12 | $17.00 | +1,490% |
Achilles Therapeutics Plc Adr Stock (ACHL) Price Forecast for 2029
The 2029 price forecast for Achilles Therapeutics Plc Adr Stock (ACHL) is $13.84 on average, with a high prediction of $16.87 and a low estimate of $10.80. This represents an +1,187% increase from the previous price of $1.075.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2029 | $16.25 | $16.49 | $16.87 | +1,412% |
February, 2029 | $15.83 | $15.96 | $16.08 | +1,372% |
March, 2029 | $14.90 | $15.16 | $15.46 | +1,286% |
April, 2029 | $14.05 | $14.60 | $14.66 | +1,207% |
May, 2029 | $13.37 | $13.44 | $13.71 | +1,144% |
June, 2029 | $13.44 | $13.23 | $12.89 | +1,150% |
July, 2029 | $13.08 | $13.29 | $13.11 | +1,116% |
August, 2029 | $12.47 | $12.60 | $12.92 | +1,060% |
September, 2029 | $12.92 | $12.32 | $12.45 | +1,102% |
October, 2029 | $11.86 | $11.93 | $12.65 | +1,004% |
November, 2029 | $11.27 | $11.32 | $11.70 | +948.52% |
December, 2029 | $10.78 | $10.80 | $11.10 | +902.69% |
Achilles Therapeutics Plc Adr Stock (ACHL) Price Forecast for 2030
Achilles Therapeutics Plc Adr Stock (ACHL) is expected to reach an average price of $6.9545 in 2030, with a high forecast of $10.58 and a low forecast of $3.3279. This signifies an +546.93% surge from the last price of $1.075.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2030 | $10.17 | $10.21 | $10.58 | +845.92% |
February, 2030 | $9.6287 | $9.7005 | $9.9855 | +795.70% |
March, 2030 | $8.9238 | $8.963 | $9.3181 | +730.12% |
April, 2030 | $8.3714 | $8.3714 | $8.7357 | +678.74% |
May, 2030 | $7.5509 | $7.5809 | $8.1633 | +602.41% |
June, 2030 | $7.0573 | $7.0985 | $7.3928 | +556.49% |
July, 2030 | $6.3705 | $6.4365 | $6.8904 | +492.61% |
August, 2030 | $5.7616 | $5.85 | $6.1634 | +435.96% |
September, 2030 | $5.2099 | $5.2412 | $5.4775 | +384.64% |
October, 2030 | $4.5117 | $4.5227 | $5.0052 | +319.69% |
November, 2030 | $3.8513 | $3.9503 | $4.2094 | +258.26% |
December, 2030 | $3.1879 | $3.3279 | $3.7022 | +196.55% |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):